Publications

Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD

Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.

The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update

Filename 308. Maurer et al., HAE Guidelines, WAO J 2018.pdf
Filesize 933 KB
Version o.308
Date added June 9, 2020
Downloaded 0 times
Category Original Work
Tags C1-inhibitor, diagnosis, GRADE, Guideline, Hereditary Angioedema, Individualized therapy, management, Prophylaxis, Quality of life, Recommendations, self-administration, therapy
Authors Maurer, M. Magerl, M., Ansotegui, I., Aygören-Pürsün, E., Betschel, S., Bork, K., Bowen, T., Balle Boysen, H., Farkas, H., Grumach, A., Hide, M., Katelaris, C., Lockey, R., Longhurst, H., Lumry, W., Martinez-Saguer, I., Moldovan, D., Nast, A., Pawankar, R., Potter, P., Riedl, M., Ritchie, B., Rosenwasser, L., Sánchez-Borges, M., Zhi, X., Zuraw, B., and Craig, T.
Citation Maurer, M., Magerl, M., Ansotegui, I., Aygören-Pürsün, E., Betschel, S., Bork, K., Bowen, T., Balle Boysen, H., Farkas, H., Grumach, A., Hide, M., Katelaris, C., Lockey, R., Longhurst, H., Lumry, W., Martinez-Saguer, I., Moldovan, D., Nast, A., Pawankar, R., Potter, P., Riedl, M., Ritchie, B., Rosenwasser, L., Sánchez-Borges, M., Zhi, X., Zuraw, B., and Craig, T.: The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. WAO Journal 2018: 11; 5.
Corresponding authors Maurer, M.
DocNum O.308
DocType PDF
Edition; Page 11; 5.
IF 3.68
Publisher WAO Journal
ReleaseDate 2018

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: 1) How should HAE-1/2 be defined and classified?, 2) How should HAE-1/2 be diagnosed?, 3) Should HAE-1/2 patients receive prophylactic and/or on-demand treatment and what treatment options should be used?, 4) Should HAE-1/2 management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and 5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures? This article is co-published with permission in Allergy and the World Allergy Organization Journal.

(Last update: 02.2021)

Number of publications (original work and reviews) in peer-reviewed journals: 601
Number of original publications in peer-reviewed journals: 432
Number of reviews in peer-reviewed journals: 169
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: 3326,21
Cumulative IF for original publications in peer-reviewed journals: 2659,47
Cumulative IF for reviews in peer-reviewed journals: 666,74
Citations, Hirsch index: (view on Web of Science) 24104